CPRX

Catalyst Pharmaceuticals Inc

31.49

Jul 14 • 03:59PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Mid NASD

Peers: RYTM MIRM PTCT KRYS BMRN VKTX INCY AXSM MDGL NBIX

| Held by: VTI VXF VTWO VIOO VHT VTWG VTHR CSA CSF ESIX

Index	-
Market Cap	3.86B
Enterprise Value	3.10B
Income	221.32M
Sales	596.96M
Book/sh	8.29
Cash/sh	6.17
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	182
IPO	Nov 08, 2006

P/E	18.10
Forward P/E	13.90
PEG	0.90
P/S	6.46
P/B	3.80
P/C	5.10
P/FCF	18.52
EV/EBITDA	10.13
EV/Sales	5.20
Quick Ratio	6.84
Current Ratio	7.10
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / No

EPS (ttm)	1.74
EPS next Y	2.27
EPS next Q	0.46
EPS this Y	12.80%
EPS next Y	19.53%
EPS next 5Y	15.37%
EPS past 3/5Y	31.19% 19.00%
Sales past 3/5Y	40.10% 37.68%
EPS Y/Y TTM	9.67%
Sales Y/Y TTM	11.65%
EPS Q/Q	12.37%
Sales Q/Q	5.63%
Earnings	May 11 AMC
EPS/Sales Surpr.	5.26% -0.12%

Insider Own	8.80%
Insider Trans	0.00%
Inst Own	83.24%
Inst Trans	-
ROA	21.52%
ROE	24.50%
ROIC	21.81%
Gross Margin	79.62%
Oper. Margin	44.83%
Profit Margin	37.08%
SMA20	0.16%
SMA50	0.90%
SMA200	24.23%
Trades

Shs Outstand	122.18M
Shs Float	111.65M
Short Float	7.03%
Short Ratio	2.97
Short Interest	7.85M
52W High	32.56 -3.29%
52W Low	19.05 65.30%
Volatility	0.07% 0.11%
ATR (14)	0.08
RSI (14)	70.17
Beta	0.75
Rel Volume	0.00
Avg Volume	2.64M
Volume	0

Perf Week	0.06%
Perf Month	0.45%
Perf Quarter	21.63%
Perf Half Y	35.91%
Perf YTD	34.92%
Perf Year	45.65%
Perf 3Y	144.87%
Perf 5Y	485.32%
Perf 10Y	4042.88%
Recom	2.40
Target Price	31.75
Prev Close	31.49
Price	31.49
Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-04-25	Initiated	Robert W. Baird	Outperform	$28
Nov-18-24	Initiated	Stephens	Overweight	$35
Mar-14-24	Initiated	Citigroup	Buy	$27
Mar-07-24	Initiated	BofA Securities	Buy	$23
Dec-21-23	Initiated	Oppenheimer	Outperform	$30
Aug-24-22	Downgrade	ROTH Capital	Buy → Neutral	$10 → $15.50
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Sep-07-18	Resumed	Piper Jaffray	Overweight
Oct-05-16	Upgrade	Piper Jaffray	Neutral → Overweight
Apr-26-16	Downgrade	Piper Jaffray	Overweight → Neutral	$6 → $1
Sep-30-14	Reiterated	ROTH Capital	Buy	$5 → $6
Sep-16-14	Reiterated	ROTH Capital	Buy	$3.50 → $5
Sep-15-14	Reiterated	H.C. Wainwright	Buy	$5 → $13
Oct-21-13	Reiterated	Aegis Capital	Buy	$4 → $5.50
Sep-24-13	Initiated	Maxim Group	Buy	$4
Sep-06-13	Reiterated	Aegis Capital	Buy	$3.50 → $4
Apr-18-13	Initiated	Aegis Capital	Buy	$2.50
Aug-27-12	Upgrade	Rodman & Renshaw	Mkt Perform → Mkt Outperform	$3.70
Oct-01-09	Upgrade	Merriman	Sell → Neutral
May-29-09	Downgrade	Merriman Curhan Ford	Buy → Sell

Show Previous Ratings

Jul-09-26 08:02PM	SEI Stock Jumps 5% After-Hours As S&P 600 Inclusion Sparks Buying (Stocktwits)
05:47PM	Solaris Energy Infrastructure Set to Join S&P SmallCap 600 (PR Newswire)
Jun-30-26 08:03AM	Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses (GlobeNewswire)
Jun-25-26 01:56PM	Are NUVL, CPRX, TMHC Obtaining Fair Deals for their Shareholders? (PR Newswire)
May-19-26 06:22PM	Are KALV, GBTG, MDV, CPRX Obtaining Fair Deals for their Shareholders? (PR Newswire)
02:56AM	Loading…
May-12-26 02:56AM	Are CPRX, UNF, RMAX, ACR Obtaining Fair Deals for their Shareholders? (PR Newswire)
May-11-26 04:50PM	Catalyst: Q1 Earnings Snapshot (Associated Press)
04:12PM	Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results (GlobeNewswire)
05:27AM	Angelini Pharma agrees $4.1bn Catalyst Pharmaceuticals acquisition (Investment Monitor)
May-08-26 05:56PM	Are CPRX, TBRG, MDV, ACR Obtaining Fair Deals for their Shareholders? (PR Newswire)
09:30AM	Italy's Angelini Pharma is acquiring Catalyst Pharmaceuticals in a $4.1 billion deal (Quartz)
09:28AM	Angelini Pharma acquires Catalyst Pharmaceuticals for $4.1 billion (Quartz)
06:05AM	Angelini Pharma to acquire Catalyst Pharmaceuticals for equity value of $4.1bn (Pharmaceutical Business Review)
May-07-26 04:02PM	Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast (GlobeNewswire)
07:20AM	Angelini to buy Catalyst in $4B play for rare neuro drugs (BioPharma Dive)
02:44AM	Loading…
02:44AM	Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE (amifampridine) Patent Litigation with Hetero Labs Ltd. (GlobeNewswire)
Apr-28-26 08:03AM	Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026 (GlobeNewswire)
Apr-15-26 07:33AM	See How Institutions Boost Catalyst Shares (FX Empire)
Mar-11-26 05:22AM	Zacks.com featured highlights include Air Lease, National Energy, Catalyst and JBT Marel (Zacks)
Mar-10-26 02:00PM	Geopolitical Volatility Boosts Value Investing: 4 Low-PEG Picks (Zacks)
01:18PM	Can Universal Health's $835M Acquisition of Talkspace Accelerate Growth? (Zacks)
11:09AM	EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y (Zacks)
10:50AM	Catalyst Pharmaceuticals: Exceptional Fundamentals Trading at 20-33% Discount (GuruFocus.com)
09:55AM	BMY Advances CELMoD Program With Positive Phase III Results (Zacks)
Mar-09-26 01:50PM	Is Community Health Systems Attractive Despite Its Heavy Debt Load? (Zacks)
12:11PM	INCY Wins EC Approval for Label Expansion of Oncology Drug Zynyz (Zacks)
12:02PM	BMY Wins FDA Nod to Expand Sotyktu Label for Psoriatic Arthritis (Zacks)
10:23AM	Roche's Giredestrant Misses Key Goal in First-Line Breast Cancer Study (Zacks)
Mar-06-26 01:25PM	Philips Unveils Rembra CT Scanner to Speed Up Medical Imaging (Zacks)
12:55PM	CYH Agreed to Sell 4 Arkansas Hospitals for $112M to Reduce Debt (Zacks)
09:57AM	Loading…
09:57AM	QURE Stock Crashes 32% in a Week: Here's What You Should Know (Zacks)
09:55AM	How Much Upside is Left in Catalyst (CPRX)? Wall Street Analysts Think 43.34% (Zacks)
09:45AM	TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS (Zacks)
09:40AM	Is American Well (AMWL) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:00AM	The Zacks Rank Explained: How to Find Strong Buy Medical Stocks (Zacks)
08:03AM	Catalyst Pharmaceuticals to Showcase Real-World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference (GlobeNewswire)
Mar-05-26 12:43PM	Bayer Advances Roundup Settlement With Missouri Court Approval (Zacks)
12:37PM	Immunovant Stock Surges 17% in 3 Months: What's Driving It? (Zacks)
09:18AM	CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data (Zacks)
08:24AM	AMRN Stock Soars 37.7% in a Year: Here's What You Need to Know (Zacks)
05:07AM	ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU (Revised) (Zacks)
Mar-04-26 12:00PM	All You Need to Know About Catalyst (CPRX) Rating Upgrade to Strong Buy (Zacks)
10:36AM	ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M (Zacks)
10:34AM	TBPH Stock Plunges 26% on Failure of Late-Stage MSA Study (Zacks)
10:00AM	Best Momentum Stock to Buy for March 4th (Zacks)
09:40AM	Are Investors Undervaluing Catalyst Pharmaceuticals (CPRX) Right Now? (Zacks)
09:03AM	Best Value Stocks to Buy for March 4th (Zacks)
08:03AM	ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU (Zacks)
05:10AM	New Strong Buy Stocks for March 4th (Zacks)
Mar-01-26 04:27AM	Catalyst Pharmaceuticals (CPRX) Reports Record Q4 and Full Year 2025 Results (Insider Monkey)
Feb-26-26 04:10PM	Catalyst Pharmaceuticals Inc (CPRX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) -7.23%
03:48PM	Catalyst Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
10:08AM	Catalyst Pharmaceuticals Q4 Earnings Beat, Firdapse Revenues Rise Y/Y (Zacks)
09:30AM	Catalyst (CPRX) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
08:30AM	Catalyst Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary (Moby)
Feb-25-26 04:07PM	Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance (GlobeNewswire)
Feb-24-26 09:50AM	Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock (Zacks)
09:15AM	Ahead of Catalyst (CPRX) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics (Zacks)
08:03AM	Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference (GlobeNewswire)
Feb-19-26 10:00AM	BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy? (Zacks)
09:40AM	Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock (Zacks)
Feb-18-26 10:00AM	Analysts Estimate Catalyst Pharmaceutical (CPRX) to Report a Decline in Earnings: What to Look Out for (Zacks)
Feb-12-26 08:45AM	Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Feb-11-26 08:03AM	Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 (GlobeNewswire)
Feb-03-26 09:40AM	Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term (Zacks)
Jan-28-26 09:50AM	Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term (Zacks)
Jan-24-26 02:20PM	2 Under-the-Radar Biotech Stocks Set to Boom in 2026 (Motley Fool)
Jan-19-26 05:18PM	Catalyst Pharmaceuticals, Inc. (CPRX): A Bull Case Theory (Insider Monkey)
Jan-16-26 12:13PM	Jim Cramer on Catalyst Pharmaceuticals: "It's a Very Inexpensive Stock" (Insider Monkey)
Jan-15-26 09:40AM	Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock (Zacks)
Jan-09-26 11:40AM	CPRX or DSNKY: Which Is the Better Value Stock Right Now? (Zacks)
Jan-08-26 09:40AM	Is Catalyst Pharmaceuticals (CPRX) Stock Undervalued Right Now? (Zacks)
08:03AM	Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies (GlobeNewswire)
Jan-05-26 08:03AM	The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS) (GlobeNewswire)
Dec-30-25 09:40AM	Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term (Zacks)
Dec-23-25 09:50AM	Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock (Zacks)
Dec-17-25 11:40AM	CPRX vs. DSNKY: Which Stock Is the Better Value Option? (Zacks)
09:55AM	Wall Street Analysts See a 42.62% Upside in Catalyst (CPRX): Can the Stock Really Move This High? (Zacks)
09:40AM	Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock? (Zacks)
09:40AM	Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-16-25 08:30AM	If You Invested $1000 in Catalyst Pharmaceutical a Decade Ago, This is How Much It'd Be Worth Now (Zacks)
Dec-15-25 02:59PM	Catalyst Pharmaceuticals Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
08:03AM	Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-10-25 10:33AM	Analysts See Big Upside in Catalyst Pharmaceuticals, Inc. (CPRX) (Insider Monkey)
Dec-09-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Dec-05-25 11:30AM	Catalyst (CPRX) Up 10% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-04-25 09:35AM	Catalyst Pharmaceutical (CPRX) Recently Broke Out Above the 20-Day Moving Average (Zacks)
09:15AM	Collegium Pharmaceutical, Inc. (COLL) Hits Fresh High: Is There Still Room to Run? (Zacks)
Dec-03-25 04:00PM	AppLovin Stock Rides Swarm Of Setups Beyond Just Mining, Medical Names (Investor's Business Daily)
Dec-02-25 09:50AM	Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term (Zacks)
Dec-01-25 11:40AM	CPRX or DSNKY: Which Is the Better Value Stock Right Now? (Zacks)
09:55AM	Wall Street Analysts Think Catalyst (CPRX) Could Surge 47.37%: Read This Before Placing a Bet (Zacks)
09:40AM	Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock? (Zacks)
09:40AM	Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-25-25 08:30AM	Here's How Much a $1000 Investment in Catalyst Pharmaceutical Made 10 Years Ago Would Be Worth Today (Zacks)
Nov-24-25 08:03AM	Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference (GlobeNewswire)
Nov-19-25 09:41AM	Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock (Zacks)
08:03AM	Catalyst Pharmaceuticals Recognized as One of North America's Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500 (GlobeNewswire)
Nov-18-25 08:03AM	Catalyst Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference (GlobeNewswire)
Nov-13-25 11:40AM	CPRX vs. ZTS: Which Stock Is the Better Value Option? (Zacks)

Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for rare neurological and neuromuscular diseases. The company markets prescription treatments for conditions such as Lambert-Eaton myasthenic syndrome, Duchenne muscular dystrophy, and epilepsy through its portfolio of approved medicines. It conducts activities across drug commercialization, regulatory management, clinical development, and patient support services for rare disease communities. Catalyst Pharmaceuticals also manages licensing and collaboration agreements related to specialty pharmaceutical products and orphan drug therapies. Its operations include medical affairs, pharmacovigilance, and programs that support patient access, reimbursement navigation, and treatment continuity.

Co-Founder & Non-Executive ChairmanMr. Patrick J. McEnany

PresidentMr. Richard John Daly M.B.A.

Executive VPMr. Michael W. Kalb CPA

Executive VPDr. Steven R. Miller Ph.D.

Executive VP & Chief Commercial OfficerMr. Jeffrey Del Carmen

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Harper Molly	Director	Dec 12 '25	Option Exercise	5.78	20,000	115,600	29,106	Dec 16 05:00 PM
Harper Molly	Director	Dec 12 '25	Sale	23.25	26,746	621,920	2,360	Dec 16 05:00 PM
Harper Molly	Director	Dec 12 '25	Proposed Sale	23.25	26,746	621,929		Dec 12 04:25 PM
Del Carmen Jeffrey	Chief Commercial Officer	Nov 26 '25	Option Exercise	4.21	10,983	46,238	14,945	Nov 28 05:00 PM
Del Carmen Jeffrey	Chief Commercial Officer	Nov 26 '25	Sale	23.33	10,983	256,244	3,962	Nov 28 05:00 PM
Del Carmen Jeffrey	Officer	Nov 26 '25	Proposed Sale	23.33	10,983	256,247		Nov 26 01:54 PM
Elsbernd Brian	Officer	Nov 12 '25	Proposed Sale	22.70	40,000	907,934		Nov 12 01:23 PM
Elsbernd Brian	Chief Compliance/Legal Officer	Sep 08 '25	Option Exercise	2.24	112,475	251,944	301,039	Sep 10 05:00 PM
Elsbernd Brian	Chief Compliance/Legal Officer	Sep 08 '25	Sale	20.30	30,000	609,000	271,039	Sep 10 05:00 PM
Elsbernd Brian	Officer	Sep 08 '25	Proposed Sale	20.30	30,000	609,035		Sep 08 02:52 PM
Elsbernd Brian	Chief Compliance/Legal Officer	Sep 04 '25	Option Exercise	2.24	30,000	67,200	218,564	Sep 05 05:00 PM
Elsbernd Brian	Chief Compliance/Legal Officer	Sep 03 '25	Option Exercise	2.24	20,000	44,800	208,564	Sep 05 05:00 PM
Elsbernd Brian	Chief Compliance/Legal Officer	Sep 04 '25	Sale	19.52	30,000	585,600	188,564	Sep 05 05:00 PM
Elsbernd Brian	Chief Compliance/Legal Officer	Sep 03 '25	Sale	20.08	20,000	401,600	188,564	Sep 05 05:00 PM
Elsbernd Brian	Officer	Sep 04 '25	Proposed Sale	19.52	30,000	585,641		Sep 04 11:28 AM
Elsbernd Brian	Officer	Sep 03 '25	Proposed Sale	20.08	20,000	401,514		Sep 03 12:19 PM
Tierney David S	Director	Aug 27 '25	Option Exercise	2.24	50,000	112,000	405,620	Aug 28 05:00 PM
Tierney David S	Director	Aug 27 '25	Sale	20.20	26,000	525,200	379,620	Aug 28 05:00 PM
Miller Steve	Chief Op. & Scientific Officer	Aug 26 '25	Option Exercise	2.24	115,000	257,600	1,064,663	Aug 28 05:00 PM
Miller Steve	Chief Op. & Scientific Officer	Aug 27 '25	Option Exercise	2.24	110,000	246,400	1,059,663	Aug 28 05:00 PM
Miller Steve	Chief Op. & Scientific Officer	Aug 26 '25	Sale	20.28	115,000	2,332,200	949,663	Aug 28 05:00 PM
Daly Richard J	President and CEO	Aug 26 '25	Option Exercise	2.24	50,000	112,000	249,764	Aug 28 05:00 PM
Daly Richard J	President and CEO	Aug 26 '25	Sale	20.62	22,970	473,641	226,794	Aug 28 05:00 PM
Tierney David S	Director	Aug 27 '25	Proposed Sale	20.20	26,000	525,088		Aug 27 04:14 PM
Miller Steve	Officer	Aug 26 '25	Proposed Sale	20.28	115,000	2,332,370		Aug 26 01:07 PM
Daly Richard J	Officer	Aug 26 '25	Proposed Sale	20.62	22,970	473,641		Aug 26 10:46 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CPRX

Catalyst Pharmaceuticals Inc

Upgrade your Finviz experience